Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Biologics Contract Development Market Grown from 2024 to 2025?
In recent times, the market size for biologics contract development has seen a significant expansion. Its growth projection shows an increase from $7.75 billion in 2024 to $8.58 billion in 2025, which translates to a compound annual growth rate (CAGR) of 10.6%. The expansion experienced during this historic period can be linked to the growth of the biologics market, the rise in biopharmaceuticals, the complexity of biologics, patent expirations, and cost efficiency.
What Growth Rate Is Anticipated for the Biologics Contract Development Market in the Coming Years?
The market size for contract development in biologics is projected to experience swift expansion in the approaching years, reaching a value of $13.19 billion in 2029 with a compound annual growth rate (CAGR) of 11.4%. The progression seen in the projected timeline can be credited to factors such as digitalization and data analytics, risk management, adaptability and scalability, significant r&d investment, precision medicine, and tailored therapies. Emerging trends over the forecast timeline involve fields such as regenerative medicine, risk reduction tactics, international collaborations, sophisticated technologies, and technology amalgamation.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp
Who Are the Leading Companies in the Biologics Contract Development Market?
Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, STC Biologics, Siegfried Evionnaz SA, BioAgilytix Labs Inc., Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., AbbVie Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Meridian Life Science Inc., Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Sartorius AG, Syngene International Limited, Vibalogics GmbH, Yposkesi
What Are the Key Drivers of the Biologics Contract Development Market?
The surge in chronic illnesses is projected to boost the biologics contract development market. Chronic illnesses are characterized by their duration of a year or more and necessitate continuous medical monitoring. The escalating number of chronic disease incidences is augmenting the need for new drug evolution, including biologics, thus fostering the growth of the biologics contract development market. For example, as per the data published by the Office for Health Improvement & Disparities, a government entity in the UK, during the initial half of 2023, there was a tally of 3,940 superfluous deaths corresponding to chronic lower respiratory maladies, indicating a 30% hike compared to anticipated rates. Throughout the year, this digit escalated to 5,363, indicating an overall 22% upsurge. Hence, the escalating prevalence of chronic illnesses contributes to the expansion of the biologics contract development market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=8219&type=smp
What Are the Key Market Segments in the Biologics Contract Development Industry?
The biologics contract development market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Others Sources
2) By Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others Indications
3) By Product Service: Cell Line Development, Process Development, Others Product Services
Subsegments:
1) By Microbial: Bacterial Sources, Yeast Sources, Fungal Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Hybridoma Cells
3) By Other Sources: Plant-Based Systems, Insect Cell Systems, Algal Sources
What Are the Latest Trends in the Biologics Contract Development Market?
The surge of technological advancements is becoming increasingly popular within the biologics contract development market. Key players in this market are incorporating cutting-edge technologies to maintain their market standing. For example, Lonza, a contract manufacturing and development solutions firm from Switzerland, introduced the bYlok technology platform in January 2022. This platform is designed to create and manufacture bispecific antibodies, addressing the issue of light-heavy chain mispairing with over 95% precision, high yields, and the capacity to retain a mAb-like format. This platform can be leveraged by pharmaceutical and biotech companies under a straightforward research license.
Access The Full Report Here:
What Are the Key Regional Markets in the Biologics Contract Development Industry?
North America was the largest region in the biologics contract development market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8219
This Report Delivers Insight On:
1. How big is the biologics contract development market, and how is it changing globally?
2. Who are the major companies in the biologics contract development market, and how are they performing?
3. What are the key opportunities and risks in the biologics contract development market right now?
4. Which products or customer segments are growing the most in the biologics contract development market?
5. What factors are helping or slowing down the growth of the biologics contract development market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
